Attovia 制药 ATTO
$15.27 +$0.27 (+1.80%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $15.27 0.00%
开盘$14.93
昨收$15.00
当日区间$14.93 – $15.50
成交量218.8K
市值$697.09M
市盈率（TTM）–
股息率–
ATTO 相关新闻
匹配 Attovia Therapeutics 或代码 ATTO 的头条新闻，按最新排序。
- LifeSci Capital Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $45
- Citi Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $30
- Analysts Offer Insights on NA Companies: Attovia Therapeutics, Inc. (ATTO) and Navan, Inc. Class A (NAVN)
- Morgan Stanley Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $39
- Analysts Offer Insights on NA Companies: Fastenal Company (FAST) and Attovia Therapeutics, Inc. (ATTO)
- RBC Capital Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $45
- U.S. Stocks Move | Biotech Company Attovia Therapeutics (ATTO.US) Debuts on Nasdaq, Closing Up 28.82% on First Trading Day
- LifeSci Capital Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $45
- RBC Capital Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $45
- Morgan Stanley Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $39
- Citi Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $30
- Goldman Sachs-backed immunotherapy startup Attovia (ATTO.US) files for Nasdaq listing: aiming to raise up to $212.5 million, becoming the latest addition to the biotech IPO boom 正面
- Citi Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $30
暂无评论——快来第一个聊聊 ATTO。
登录后参与讨论。